Iroko secures $75m in debt for Zorvolex launch
This article was originally published in Scrip
Iroko Pharmaceuticals pursued an initial public offering earlier this year, but later decided to rely on private investors – including a new debt provider – ahead of US FDA approval for the first few nonsteroidal anti-inflammatory drugs (NSAIDs) in the company's pipeline.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.